Eisai Submits Injectable Version of Leqembi to FDA

Published on May 15, 2024

Eisai and partner Biogen said on Tuesday that the Japanese drugmaker has begun submitting data on a rolling basis to the US health regulator for a marketing application of a subcutaneous form of their Alzheimer’s disease drug Leqembi. The companies are seeking the Food and…

Read Full Article (External Site)